IceCure Medical Reports Data From Its Kidney Cancer Clinical Study Presented At Interventional Radiology Conference Dsud Minimally Invasive Approach Results In Shorter Hospitalization And Minor Impact On Renal Function
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical Ltd. (NASDAQ:ICCM) presented interim data from its ICESECRET kidney cancer trial at the 3rd Annual Israeli Conference on Interventional Radiology. The data showed that the ProSense® System is safe and effective, with an 89.5% recurrence-free rate. More data is expected in Q4 2024.
June 12, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IceCure Medical presented interim data from its ICESECRET kidney cancer trial, showing an 89.5% recurrence-free rate. The ProSense® System is approved for treating kidney tumors in the U.S., Europe, and other countries. More data is expected in Q4 2024.
The positive interim results and the high recurrence-free rate are likely to boost investor confidence in IceCure Medical. The approval of ProSense® in multiple regions and the anticipation of more data in Q4 2024 further support a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100